

**Supplemental Table 1.** Univariate analysis of recurrence-free survival

<b>Variable</b>	<b>Hazard Ratio (95% CI)</b>	<b>p value</b>
<b>Age at liver resection</b>	1 (0.99-1.01)	0.687
<b>Body mass index</b>	0.99 (0.96-1.02)	0.549
<b>Number of resected liver segments</b>	1.13 (1.02-1.25)	0.014
<b>Adjuvant treatment group</b>		0.046
HAIC+Sys	1	
Sys	1.53 (1.07-2.18)	
Surgery alone	1.41 (0.99-2.02)	
<b>Sex</b>		0.917
Male	1	
Female	1.02 (0.76-1.35)	
<b>Location of primary</b>		0.017
Right colon	1	
Left colon	0.6 (0.41-0.86)	
Rectum	0.76 (0.5-1.15)	
<b>Nodal status of primary</b>		0.143
N1	1	
N2	1.25 (0.93-1.69)	
<b>Type of chemotherapy after primary resection</b>		0.215
5-FU alone	1	
5-FU + oxaliplatin/irinotecan	1.23 (0.89-1.71)	
<b>CRS</b>		<0.001
Low risk (0-3)	1	
High risk (4-5)	2.37 (1.5-3.74)	
<b>Disease-free interval (DFI)</b>		0.127
≥12 months	1	
<12 months	1.25 (0.94-1.66)	
<b>Number of liver tumors</b>		0.004
Single lesion	1	
Multiple lesions	1.53 (1.15-2.04)	
<b>Largest CLM tumor size</b>		0.002
≤5 cm	1	
>5 cm	1.67 (1.19-2.33)	
<b>CEA prior to hepatectomy</b>		0.014
≤200 µg/L	1	
>200 µg/L	2.01 (1.14-3.54)	
<b>Neoadjuvant chemotherapy prior hepatectomy</b>		0.131
No	1	
Yes	1.36 (0.91-2.04)	
<b>Surgical era</b>		0.802
1992-2001	1	

2002-2014

1.04 (0.77-1.39)

HAIC=hepatic arterial infusion chemotherapy; Sys=systemic chemotherapy; 5-FU=5-fluorouracil;

CRS=clinical risk score; CLM=colorectal liver metastasis; CEA=carcinoembryonic antigen

Journal Pre-proof

**Supplemental Table 2.** Univariate analysis of overall survival

<b>Variable</b>	<b>Hazard Ratio (95% CI)</b>	<b><i>p</i> value</b>
<b>Age at liver resection</b>	1.01 (1-1.02)	0.227
<b>Body mass index</b>	0.98 (0.95-1.02)	0.315
<b>Number of resected liver segments</b>	1.1 (0.99-1.23)	0.063
<b>Adjuvant treatment group</b>		0.008
HAIC+Sys	1	
Sys	1.71 (1.17-2.49)	
Surgery alone	1.7 (1.15-2.5)	
<b>Sex</b>		0.271
Male	1	
Female	1.19 (0.87-1.62)	
<b>Location of primary</b>		0.037
Right Colon	1	
Left Colon	0.61 (0.41-0.89)	
Rectum	0.73 (0.46-1.14)	
<b>Nodal status of primary</b>		0.363
N1	1	
N2	1.16 (0.84-1.61)	
<b>Type of chemotherapy after primary resection</b>		0.362
5-FU alone	1	
5-FU + Oxaliplatin/Irinotecan	0.84 (0.57-1.23)	
<b>CRS</b>		<0.001
Low risk (0-3)	1	
High risk (4-5)	2.44 (1.52-3.9)	
<b>Disease-free interval (DFI)</b>		0.715
≥12 months	1	
<12 months	1.06 (0.78-1.44)	
<b>Number of liver tumors</b>		0.073
Single lesion	1	
Multiple lesions	1.32 (0.97-1.8)	
<b>Largest CLM tumor size</b>		<0.001
≤5 cm	1	
>5 cm	1.84 (1.3-2.6)	
<b>CEA prior to hepatectomy</b>		0.019
≤200 μg/L	1	
>200 μg/L	2 (1.11-3.61)	
<b>Neoadjuvant chemotherapy prior hepatectomy</b>		0.725
No	1	
Yes	0.92 (0.59-1.45)	
<b>Surgical era</b>		0.153
1992-2001	1	

2002-2014

0.79 (0.57-1.09)

HAIC=hepatic arterial infusion chemotherapy; Sys=systemic chemotherapy; 5-FU=5-fluorouracil;

CRS=clinical risk score; CLM=colorectal liver metastasis; CEA=carcinoembryonic antigen

Journal Pre-proof